Cantor Fitzgerald Issues Negative Forecast for LLY Earnings

Key Points

• Cantor Fitzgerald has revised their FY2025 earnings per share estimate for Eli Lilly and Company from $23.25 to $23.00, maintaining an "Overweight" rating with a price target of $925.00 on the stock.
• In their last earnings report, Eli Lilly exceeded expectations with $6.31 earnings per share and reported $15.56 billion in revenue, marking a 37.6% increase year-over-year.
• Institutional investors hold 82.53% of Eli Lilly's stock, with significant stake increases reported by PNC Financial Services and Vanguard Group, reflecting strong investor confidence despite recent earnings forecast adjustments.

Eli Lilly and Company (NYSE:LLY - Free Report) - Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for Eli Lilly and Company in a research note issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the company will post earnings per share of $23.00 for the year, down from their previous estimate of $23.25. Cantor Fitzgerald has a "Overweight" rating and a $925.00 price target on the stock. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS.

Other equities analysts have also issued research reports about the company. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. UBS Group cut their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a report on Friday. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $948.06.

Eli Lilly and Company Stock Down 2.6%

LLY opened at $833.08 on Monday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a fifty day moving average of $742.42 and a two-hundred day moving average of $765.55. The stock has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.18 and a beta of 0.47.

Insiders Place Their Bets

In related news, Director Gabrielle Sulzberger purchased 117 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Vanguard Group Inc. grew its position in Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company's stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares during the period. Wellington Management Group LLP grew its position in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after acquiring an additional 81,587 shares during the period. Laurel Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company's stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Finally, Norges Bank purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth $8,827,714,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.